Major depressive disorder, recurrent, in partial remission
Methodology & AI Transparency ⓘ
Major depressive disorder, recurrent, in partial remission Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Recognized across U.S.
- 2 Real-world patient consensus: Clinical coding for Major depressive disorder, recurrent, in partial remission uses ICD-10 F33.41 across Depression & Mood specialty care.
- 3 Typical cash cost range: Differential triage of Major depressive disorder, recurrent, in partial remission (F33.41) utilizes sleep-wake rhythm assessment [Major depressive disorder, recurrent, in partial remission F33.41].
- 4 Top reported side effects / signs: Objective lab/clinical target for Major depressive disorder, recurrent, in partial remission: PHQ-9 Symptom Severity in Major depressive disorder, recurrent, in partial remission (F33.41: Score) (< 4 (clinical remission) (F33.41)) and TSH & Free in Major depressive disorder, recurrent, in partial remission (F33.41: T4 Rule-Out).
Ask our AI Specialists anything about Major depressive disorder, recurrent, in partial remission
What Is Major depressive disorder, recurrent, in partial remission?
Recognized across U.S. clinical coding as F33.41 (Depression & Mood), Major depressive disorder, recurrent, in partial remission is evaluated via sleep-wake rhythm assessment [Major depressive disorder, recurrent, in partial remission F33.41] to align day-to-day symptom relief with long-term physiological stability.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Major depressive disorder, recurrent, in partial remission (ICD-10 F33.41) is driven by circadian phase instability [Major depressive disorder, recurrent, in partial remission F33.41]; specialists in Depression, Bipolar & Mood Disorders monitor TSH & Free in Major depressive disorder, recurrent, in partial remission (F33.41: T4 Rule-Out) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Major depressive disorder, recurrent, in partial remission (F33.41): slowed concentration, indecisiveness, in Major depressive disorder, recurrent, in partial remission (F33.41: and physical heaviness)
- • Secondary Major depressive disorder, recurrent, in partial remission clinical sign: loss of interest in Major depressive disorder, recurrent, in partial remission (F33.41: or pleasure in)
- • Symptom flares in Major depressive disorder, recurrent, in partial remission correlating with PHQ-9 Symptom Severity in Major depressive disorder, recurrent, in partial remission (F33.41: Score) deviation outside < 4 (clinical remission) (F33.41)
- • Functional depression & mood impact requiring sleep-wake rhythm assessment [Major depressive disorder, recurrent, in partial remission F33.41] evaluation (F33.41)
Major depressive disorder, recurrent, in partial remission Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F33.41 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Depression, Bipolar & Mood Disorders | NLM Clinical Tables |
| Diagnostic / Lab Marker: PHQ-9 Symptom Severity in Major depressive disorder, recurrent, in partial remission (F33.41: Score) | < 4 (clinical remission) (F33.41) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: TSH & Free in Major depressive disorder, recurrent, in partial remission (F33.41: T4 Rule-Out) | TSH 0.8 – 2.5 mIU/L (F33.41) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Vitamin D in Major depressive disorder, recurrent, in partial remission (F33.41: & RBC Folate) | 25(OH)D 40 – 65 ng/mL (F33.41) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Major depressive disorder, recurrent, in partial remission
Treatment selection for Major depressive disorder, recurrent, in partial remission depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Major depressive disorder, recurrent, in partial remission)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake: What a 10,039-Participant Study Found Higher doses of SSRIs appear slightly more effective in depression. The American journal of psychiatry • 2016-02-01 • Meta-Analysis | N = 10,039 | 99/100 | PMID 26552940 ↗ |
| New Insights on Pharmacological and non-pharmacological treatments for depression in: What a 10,991-Participant Study Found Herbal medicine and mirtazapine had no significant difference in overall risk of side effects compared with placebo. Psychiatry research • 2019-11-15 • Meta-Analysis | N = 10,991 | 99/100 | PMID 31627074 ↗ |
| New Insights on Efficacy and tolerability of antidepressant drugs in treatment of depression in: What a 6,949-Participant Study Found A total of 33 RCTs were included in 32 articles, involving 6949 patients. Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences • 2022-08-01 • Meta-Analysis | N = 6,949 | 99/100 | PMID 37202104 ↗ |
| New Insights on Antidepressants for the treatment of adults with depression in the maintenance: What a 9,384-Participant Study Found Compared to placebo, venlafaxine was associated with a lower incidence of dizziness, while desvenlafaxine, sertraline, and vortioxetine were associated with a higher incidence of nausea/vomiting. Molecular psychiatry • 2023-01-15 • Meta-Analysis | N = 9,384 | 99/100 | PMID 36253442 ↗ |
| New Insights on Modeling the efficacy of a novel antidepressant zuranolone for: What a 8,735-Participant Study Found Primary side effects related to zuranolone included somnolence, headache, dizziness, and sedation, with no severe safety signals observed. Journal of affective disorders • 2026-01-01 • Meta-Analysis | N = 8,735 | 99/100 | PMID 40876640 ↗ |
Major depressive disorder, recurrent, in partial remission Patient Community & “People Like Me” Threads
Filter Major depressive disorder, recurrent, in partial remission community threads and patient logs by age, biological sex, dosage, and treatment duration.